中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (2): 161-164.doi: 10.35541/cjd.20201028
宋志强 王欢
收稿日期:2020-10-21
修回日期:2020-12-01
发布日期:2021-01-29
通讯作者:
宋志强
E-mail:zhiqiang.song@hotmail.com
Song Zhiqiang, Wang Huan
Received:2020-10-21
Revised:2020-12-01
Published:2021-01-29
Contact:
Song Zhiqiang
E-mail:zhiqiang.song@hotmail.com
摘要： 【摘要】 特应性皮炎是一种反复发作的炎症性皮肤病，现有的治疗方法虽能缓解症状，但仍存在一定的局限性及不良反应。近年来，随着特应性皮炎关键炎症分子的发现和靶向治疗药物的开发，给临床带来一些新的治疗方法和理念。了解特应性皮炎相关生物制剂、小分子药物、辅助治疗、监测手段和疾病管理模式新进展，有助于临床医生更好地治疗及管理特应性皮炎患者。
宋志强 王欢. 特应性皮炎的治疗进展：新药物、新手段、新模式[J]. 中华皮肤科杂志, 2021,54(2):161-164. doi:10.35541/cjd.20201028
Song Zhiqiang, Wang Huan. Advances in the treatment of atopic dermatitis: new medications, new methods and new models[J]. Chinese Journal of Dermatology, 2021, 54(2): 161-164.doi:10.35541/cjd.20201028
| ［1］ | 中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. doi: 10.35541/cjd.20191000. |
| ［2］ | Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis［J］. J Am Acad Dermatol, 2014,70（2）:338⁃351. doi: 10.1016/j.jaad.2013.10.010. |
| ［3］ | Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema （atopic dermatitis） part II［J］. J Eur Acad Dermatol Venereol, 2012,26（9）:1176⁃1193. doi: 10.1111/j.1468⁃3083.2012.04636.x. |
| ［4］ | Ahn K, Kim BE, Kim J, et al. Recent advances in atopic dermatitis［J］. Curr Opin Immunol, 2020,66:14⁃21. doi: 10.1016/j.coi.2020.02.007. |
| ［5］ | Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS［J］. J Am Acad Dermatol, 2020,82（6）:1328⁃1336. doi: 10.1016/j.jaad.2020.02.060. |
| ［6］ | Beck LA, Thaçi D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open⁃label study of adults with moderate⁃to⁃severe atopic dermatitis［J］. Am J Clin Dermatol, 2020,21（4）:567⁃577. doi: 10.1007/s40257⁃020⁃00527⁃x. |
| ［7］ | de Bruin⁃Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin a or when this treatment is medically inadvisable: a placebo⁃controlled, randomized phase III clinical trial （LIBERTY AD CAFÉ）［J］. Br J Dermatol, 2018,178（5）:1083⁃1101. doi: 10.1111/bjd.16156. |
| ［8］ | Wang C, Kraus CN, Patel KG, et al. Real⁃world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients′ records［J］. Int J Dermatol, 2020,59（2）:253⁃256. doi: 10.1111/ijd.14573. |
| ［9］ | Wollenberg A, Howell MD, Guttman⁃Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti⁃IL⁃13 mAb［J］. J Allergy Clin Immunol, 2019,143（1）:135⁃141. doi: 10.1016/j.jaci. 2018.05.029. |
| ［10］ | Pavel AB, Song T, Kim HJ, et al. Oral Janus kinase/SYK inhibition （ASN002） suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis［J］. J Allergy Clin Immunol, 2019,144（4）:1011⁃1024. doi: 10.1016/j.jaci.2019.07.013. |
| ［11］ | Bissonnette R, Maari C, Forman S, et al. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate⁃to⁃severe atopic dermatitis: results from a randomized double⁃blind placebo⁃controlled study［J］. Br J Dermatol, 2019,181（4）:733⁃742. doi: 10.1111/bjd.17932. |
| ［12］ | Silverberg JI, Tallman AM, Ports WC, et al. Evaluating the efficacy of crisaborole using the atopic dermatitis severity index and percentage of affected body surface area［J］. Acta Derm Venereol, 2020,100（13）:adv00170. doi: 10.2340/00015555⁃3489. |
| ［13］ | Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream （JAK1/JAK2 inhibitor） or triamcinolone cream［J］. J Allergy Clin Immunol, 2020,145（2）:572⁃582. doi: 10.1016/j.jaci.2019.08.042. |
| ［14］ | Nakatsuji T, Chen TH, Narala S, et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis［J］. Sci Transl Med, 2017,9（378）:eaah4680. doi: 10.1126/scitranslmed.aah4680. |
| ［15］ | Yoo J, Choi JY, Lee BY, et al. Therapeutic effects of saline groundwater solution baths on atopic dermatitis: a pilot study［J］. Evid Based Complement Alternat Med, 2020,2020:8303716. doi: 10.1155/2020/8303716. |
| ［16］ | Maarouf M, Shi VY. Bleach for atopic dermatitis［J］. Dermatitis, 2018,29（3）:120⁃126. doi: 10.1097/DER.0000000000000358. |
| ［17］ | Fishbein AB, Lor J, Penedo FJ, et al. Patient⁃reported outcomes for measuring sleep disturbance in pediatric atopic dermatitis: cross sectional study of PROMIS pediatric sleep measures and actigraphy［J］. J Am Acad Dermatol, 2020,S0190⁃9622（20）31015⁃X. doi: 10.1016/j.jaad. 2020.05.138. |
| ［18］ | Gustafson CJ, O′Neill J, Hix E, et al. Feasibility of actigraphy wristband monitoring of atopic dermatitis in children［J］. Skin Res Technol, 2014,20（4）:510⁃514. doi: 10.1111/srt.12147. |
| ［19］ | Dong B, Ren A, Shah SA, et al. Monitoring of atopic dermatitis using leaky coaxial cable［J］. Healthc Technol Lett, 2017,4（6）:244⁃248. doi: 10.1049/htl.2017.0021. |
| ［20］ | Eto H, Tsuji G, Chiba T, et al. Non⁃invasive evaluation of atopic dermatitis based on redox status using in vivo dynamic nuclear polarization magnetic resonance imaging［J］. Free Radic Biol Med, 2017,103:209⁃215. doi: 10.1016/j.freeradbiomed.2016.12. 043. |
| ［21］ | Wenninger K, Kehrt R, von Rüden U, et al. Structured parent education in the management of childhood atopic dermatitis: the Berlin model［J］. Patient Educ Couns, 2000,40（3）:253⁃261. doi: 10.1016/s0738⁃3991（99）00074⁃9. |
| ［22］ | van Os⁃Medendorp H, Deprez E, Maes N, et al. The role of the nurse in the care and management of patients with atopic dermatitis［J］. BMC Nurs, 2020,19（1）:102. doi: 10.1186/s12912⁃020⁃00494⁃y. |
| ［23］ | 赖沙, 王华. 特应性皮炎治疗中的患者教育和管理［J］. 国际皮肤性病学杂志, 2013,39（4）:255⁃257. doi: 10.3760/cma.j.issn. 1673⁃4173.2013.04.014. |
| ［24］ | 蒲晓英. 全程健康教育对银屑病患者生活质量的影响［J］. 中国医疗前沿, 2013,（10）:110⁃111. doi: 10.3969/j.issn.1673⁃5552. 2013.10.0082. |
| [1] | 张宁, 李舒, 李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 0(4): 20200767-e20200767. |
| [2] | 李妍 李明 徐薇 李邻峰. 【开放获取】丙酸氟替卡松乳膏单独或联合卡泊三醇软膏治疗轻中度斑块状银屑病的随机自身对照研究[J]. 中华皮肤科杂志, 2022, 55(3): 260-263. |
| [3] | 李锁 向睿宇 李志量 荆可 王媛 张寒梅 冯素英. 盐裂皮肤间接免疫荧光技术在大疱性类天疱疮诊断中的价值评估[J]. 中华皮肤科杂志, 2022, 55(3): 235-237. |
| [4] | 吕玲 吕小岩. 皮肌炎伴发恶性肿瘤的研究进展[J]. 中华皮肤科杂志, 2022, 55(3): 276-279. |
| [5] | 李浩, 王俐 韩宪伟 孙彤 苏芳 孙晓冬 韩莹 杨国玲 刘晓明 王凯波 . 糖尿病患者服用二肽基肽酶Ⅳ抑制剂后发生大疱性类天疱疮32例临床特征分析[J]. 中华皮肤科杂志, 2022, 55(3): 213-218. |
| [6] | 《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）[J]. 中华皮肤科杂志, 2022, 55(3): 187-195. |
| [7] | 王娟娟 陈容 季江 苏文星 魏钰倩 赵莹 尹兴平 苏玉华 施辛. 以精神行为异常为首发症状的67例神经梅毒患者回顾性分析[J]. 中华皮肤科杂志, 2022, 55(3): 231-234. |
| [8] | 温广东 冒丹丹 张原媛 窦沅青 赵培 吴晨雨 张建中. 【开放获取】度普利尤单抗治疗泛发性苔藓状淀粉样变1例国内首报[J]. 中华皮肤科杂志, 2022, 0(2): 20210694-e20210694. |
| [9] | 李赛, 薛华忠, 张树文, 蒋娟, 齐淑贞, 赵园园, 张津萍, 沙仲, 乐文静, 王碧伟, 赵诗轩, 朱小凤, 苏晓红. 多西环素-莫西沙星序贯疗法治疗生殖支原体尿道炎/宫颈炎的临床观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210631-e20210631. |
| [10] | 焦晓燕, 尹光文, 阴亚坤, 李冬芹. 妊娠期、围生期带状疱疹25例临床分析[J]. 中华皮肤科杂志, 2022, 0(2): 20210384-e20210384. |
| [11] | 王佳绮, 王平, 李刘雨, 樊奇敏, 朱蒙燕, 王燕清, 周鸿宇, 沈宏, 许爱娥. 皮肤色素减退性淋巴增殖性疾病41例临床病理分析[J]. 中华皮肤科杂志, 2022, 55(2): 110-115. |
| [12] | 林羽洁, 刘凤洁, 高玉梅, 刘向君, 许卜方, 李映依, 赖盼, 陈卓婧, 孙婧茹, 涂平, 汪旸. 溶血磷脂酸受体6在蕈样肉芽肿向大细胞转变中的意义及其对皮肤T细胞淋巴瘤细胞增殖和凋亡的影响[J]. 中华皮肤科杂志, 2022, 55(2): 102-109. |
| [13] | 王慧, 刘董, 田芳, 魏志平. 表皮生长因子受体shRNA联合西罗莫司对Colo-16细胞体外增殖、凋亡的研究[J]. 中华皮肤科杂志, 2022, 55(2): 135-141. |
| [14] | 欧敏, 颜韵灵, 郑宝庆, 王晓华. 银屑病与肥胖相关性的研究进展[J]. 中华皮肤科杂志, 2022, 55(2): 181-184. |
| [15] | 包诗杰, 程杨, 晏莹, 范昉, 高婷婷, 冯小兰, 郑亮, 雷卫, 黄琴斯, 张伟明, 周小勇. 人免疫球蛋白和重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中毒性表皮坏死松解症的对比研究[J]. 中华皮肤科杂志, 2022, 55(2): 153-156. |
|
